↓ Skip to main content

Segurança da vacina papillomavirus humano 6, 11, 16 e 18 (recombinante): revisão sistemática e metanálise

Overview of attention for article published in Revista Paulista de Pediatria, December 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#3 of 374)
  • High Attention Score compared to outputs of the same age (92nd percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

blogs
2 blogs
twitter
7 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
28 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Segurança da vacina papillomavirus humano 6, 11, 16 e 18 (recombinante): revisão sistemática e metanálise
Published in
Revista Paulista de Pediatria, December 2015
DOI 10.1016/j.rpped.2015.02.006
Pubmed ID
Authors

Pedro Luiz Spinelli Coelho, Gustavo Lacerda da Silva Calestini, Fernando Salgueiro Alvo, Jefferson Michel de Moura Freitas, Paula Marcela Vilela Castro, Tulio Konstantyner

Abstract

To identify and quantify the adverse effects associated with the recombinant human papillomavirus (types 6, 11, 16 and 18) vaccine in adolescents. Systematic review of randomized clinical trials from PubMed, SciELO and Lilacs databases. Articles investigating the safety of the vaccine in subjects under 18 years and comparing the recombinant human papillomavirus types 6, 11, 16 and 18 vaccine with a control group were included. Meta-analyses were performed for the outcomes of pain, erythema, swelling and fever, using clinical trials with maximum Jadad score. Fourteen studies were included. The most commons adverse effects related to the human papillomavirus vaccine were effects with no severity (pain, erythema, edema, and fever). Five studies were used for the meta-analyses: Pain-Risk Difference (RD)=11% (p<0.001); edema-RD=8% (p<0.001); erythema-RD=5% (p<0.001); fever-RD=2% (p<0.003). The recombinant human papillomavirus types 6, 11, 16 and 18 vaccine was safe and well tolerated. The main adverse effects related to vaccination were pain, erythema, edema and fever. The low frequency of severe adverse effects encourages the administration of the vaccine in the population at risk.

Twitter Demographics

The data shown below were collected from the profiles of 7 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 28 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 10 36%
Student > Master 4 14%
Student > Doctoral Student 2 7%
Student > Ph. D. Student 1 4%
Researcher 1 4%
Other 1 4%
Unknown 9 32%
Readers by discipline Count As %
Medicine and Dentistry 5 18%
Nursing and Health Professions 3 11%
Pharmacology, Toxicology and Pharmaceutical Science 2 7%
Engineering 2 7%
Immunology and Microbiology 1 4%
Other 3 11%
Unknown 12 43%

Attention Score in Context

This research output has an Altmetric Attention Score of 22. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 September 2018.
All research outputs
#1,066,501
of 17,361,274 outputs
Outputs from Revista Paulista de Pediatria
#3
of 374 outputs
Outputs of similar age
#26,550
of 376,498 outputs
Outputs of similar age from Revista Paulista de Pediatria
#1
of 7 outputs
Altmetric has tracked 17,361,274 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 374 research outputs from this source. They receive a mean Attention Score of 2.0. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 376,498 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them